Clinical trials: Relapsing-remitting Multiple Sclerosis, open to volunteers
Relapsing-remitting Multiple Sclerosis
The HIt HArd and hiT Early in Multiple Sclerosis Trial
The HiHat trial is a Phase 2 study aimed at evaluating the safety and feasibility of sequential treatment with rituximab and cladribine in patients with relapsing-remitting multiple sclerosis (RRMS).
- Trial name
- HiHat (NCT07517185)
- Testing
- Sequential treatment with rituximab and cladribine
- Where
- 4 sites in Sweden
- Volunteers
- 60 people
- Sponsor
- Uppsala University
Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
This is a multi-center prospective rater-masked (blinded) randomized controlled trial of 156 participants, comparing the treatment strategy of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) to the treatment strategy…
- Conditions
- Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
- Trial name
- BEAT-MS (NCT04047628)
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Best Available Therapy (BAT)
- Where
- 23 sites in United States
- Volunteers
- 156 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Relapsing-remitting Multiple Sclerosis
A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)
The main purpose of this study is to evaluate the pharmacokinetics (PK) of ocrelizumab administered subcutaneously (SC) in children and adolescents aged 10 to <18 years with RRMS.
- Trial name
- Operetta III (NCT07503340)
- Testing
- Ocrelizumab co-formulated with rHuPH20
- Volunteers
- 25 people
- Sponsor
- Hoffmann-La Roche
Multiple Sclerosis, Relapsing-Remitting
Identifying Immune Biomarkers of Disease and Disease Control in Autoimmune Neurological Disease Using Autologous Haematopoietic Stem Cell Transplantation
The underlying disease mechanisms which occur in patients with immune mediation neurological diseases, such as Multiple Sclerosis (MS), are incompletely understood.
- Trial name
- BIO-MS (NCT06195800)
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Relapsing-Remitting Multiple Sclerosis
Non-interventional Study of Subcutaneous Ocrelizumab in Persons With Relapsing-Remitting Multiple Sclerosis
The main purpose of the study is to assess patient-reported satisfaction with subcutaneous (s.c.) ocrelizumab administration in participants with relapsing-remitting multiple sclerosis (RRMS) who are treatment-naive, switching…
- Trial name
- SONATA-MS (NCT07827586)
- Testing
- Ocrelizumab
- Where
- Slovenia
- Volunteers
- 1,800 people
- Sponsor
- Hoffmann-La Roche
Multiple Sclerosis, Relapsing-Remitting, Fatigue
Fatigue Alleviation Through Neuromodulating Therapy in Multiple Sclerosis
The goal of this clinical trial is to learn if repetitive Transcranial Magnetic Stimulation (rTMS) of the left premotor cortex can lessen fatigue in patients with Multiple Sclerosis, and if this is a feasible intervention.
- Trial name
- FANTiMS (NCT06569550)
- Testing
- Real Repetitive Transcranial Magnetic Stimulation
- Where
- Denmark
- Volunteers
- 60 people
- Sponsor
- Danish Research Centre for Magnetic Resonance
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Chronic Progressive
Clinnova-MS: A Prospective Cohort Study of Patients With Multiple Sclerosis: A Trans-regional Digital Health Effort Unlocking the Potential of Artificial Intelligence and Data Science in Health Care
The Clinnova-Multiple Sclerosis (MS) study is part of the Clinnova program (NCT06526364; NCT06235684 and NCT05733702), which seeks to advance precision medicine and the digitalization of healthcare through high-quality…
- Conditions
- Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Chronic Progressive, Clinically Isolated Syndrome, Primary Progressive Multiple Sclerosis
- Trial name
- Clinnova-MS (NCT07280871)
- Testing
- Cohort
- Where
- Luxembourg
- Volunteers
- 100 people
- Sponsor
- Luxembourg Institute of Health
Relapsing Remitting Multiple Sclerosis
A Study to Evaluate the Preliminary Efficacy and Safety of Terfenadine in Patients With Relapsing-Remitting Multiple Sclerosis
The goal of this clinical trial is to evaluate the safety and tolerability of terfenadine when added to standard first-line disease-modifying therapy in adults with multiple sclerosis.
- Trial name
- NCT07827716
- Testing
- Terfenadine, Standard First-line Disease-Modifying Therapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Chuan Qin
Multiple Sclerosis, Relapsing-Remitting
Treatment of Cognitive Deficits in Multiple Sclerosis With High-Definition Transcranial Direct Current Stimulation
The purpose of the study is to test whether low level electric stimulation, called transcranial Direct Current Stimulation (tDCS), on the part of the brain (i.e., presupplementary motor area) thought to aid in memory will improve…
- Trial name
- MS-HDtDCS (NCT05958381)
- Testing
- Transcranial Direct Current Stimulation
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- The University of Texas at Dallas
Multiple Sclerosis, Relapsing-Remitting
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
The purpose of this study is to evaluate the effectiveness, safety, tolerability, drug levels and drug effects of ozanimod compared to fingolimod in children and adolescents with relapsing remitting multiple sclerosis (RRMS).
- Trial name
- NCT06408259
- Testing
- Ozanimod, Fingolimod
- Where
- 33 sites in United States, Australia and 9 more
- Volunteers
- 194 people
- Sponsor
- Bristol-Myers Squibb
Relapsing Remitting Multiple Sclerosis, Primary Progressive Multiple Sclerosis
SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis
The study seeks to investigate safety and efficacy of ixazomib (NINLARO), a proteasome inhibitor, in multiple sclerosis (MS). Participants will receive either ixazomib capsules or placebo capsules for up to 24 months.
- Conditions
- Relapsing Remitting Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
- Trial name
- SIZOMUS (NCT03783416)
- Where
- United Kingdom
- Volunteers
- 72 people
- Sponsor
- Queen Mary University of London
Relapsing Remitting Multiple Sclerosis
The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study
The MS pilot study will assess the safety and investigate the remyelinating effects of the SetPoint System (study device) in adult patients diagnosed with relapsing-remitting multiple sclerosis (RRMS).
- Trial name
- NCT06796504
- Testing
- Implant Procedure, Disease-Modifying Therapies (DMTs), Active stimulation
- Where
- 9 sites in United States
- Volunteers
- 60 people
- Sponsor
- SetPoint Medical Corporation
Relapsing-remitting Multiple Sclerosis (RRMS)
A Study of Rocbrutinib in PRL-Positive Relapsing-Remitting Multiple Sclerosis
This is a randomized, controlled, multicenter, open-label Phase IIa clinical study to evaluate the efficacy and safety of rocbrutinib (LP-168), an oral BTK inhibitor, in subjects with paramagnetic rim lesion (PRL)-positive…
- Trial name
- NCT07776743
- Testing
- Rocbrutinib, Dimethyl Fumarate
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Guangzhou Lupeng Pharmaceutical Company LTD.
Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Secondary Progressive
A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS
The study is an investigator-run, study following participants for 2 years with twice-daily remibrutinib. MRI is the main endpoint. Safety, tolerability, and efficacy are secondary endpoints.
- Conditions
- Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Secondary Progressive, Multiple Sclerosis (MS) Primary Progressive
- Trial name
- RemiSeven (NCT07222956)
- Testing
- Remibrutinib (Open Label)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Moein Amin
Multiple Sclerosis (MS) - Relapsing-remitting
Brain Imaging and Immune Changes During Remibrutinib Treatment in Multiple Sclerosis.
REDEFINE-MS is a research study for people with relapsing multiple sclerosis (MS) who are participating in the RESHAPE-MS trial.
- Trial name
- REDIFINE MS (NCT07758270)
- Testing
- Remibrutinib, Ocrelizumab (US)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Washington University School of Medicine
Multiple Sclerosis (MS) - Relapsing-remitting
Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple Sclerosis
The purpose of the research study is to explore new retinal imaging biomarkers of immune cell activity in MS during use of ublituximab (Briumvi) treatment.
- Trial name
- NCT06864936
- Testing
- Ublituximab, Other disease modifying therapies
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Maryland, Baltimore
Multiple Sclerosis
Sociocognitive Intervention and Rehabilitation Program in Multiple Sclerosis
Multiple Sclerosis (MS) is a chronic autoimmune disease of the central nervous system, involving inflammation, demyelination, and neurodegeneration. It is the most common non-traumatic disabling disease affecting young adults.
- Trial name
- REACT-MS (NCT07734675)
- Testing
- Sociocognitive rehabilitation via COGWEB platform combined with an emotional processing intervention.
- Where
- 2 sites in Portugal
- Volunteers
- 130 people
- Sponsor
- Sonia Batista
Multiple Sclerosis (MS) Relapsing Remitting
Effects of Powered Hip Flexion Device in Persons With Multiple Sclerosis
The purpose of this study is to assess the immediate effects of a commercially available non-FDA regulated powered hip flexion assist device (Hypershell X, Shenzhen, China) on walking ability in persons with MS.
- Trial name
- NCT07724093
- Testing
- Powered Hip Flexion Orthosis (Hypershell X)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Dayton
Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis
Study to Investigate Vagus Nerve Stimulation Paired With Motor Task for Remyelination and Functional Recovery
The goal of this clinical trial is to learn if stimulating the vagus nerve in combination with a motor task in people with multiple sclerosis can improve motor function.
- Trial name
- NCT06641271
- Testing
- Closed Loop Trans-Auricular Vagus Nerve Stimulation System
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- University of Colorado, Denver
Multiple Sclerosis (MS), Multiple Sclerosis, Relapsing-Remitting
Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy
The clinical trial is intended to assess for clinical evidence of Clemastine Fumarate as a myelin repair therapy in patients with chronic inflammatory injury-causing demyelination as measured by multi-parametric MRI assessments.
- Conditions
- Multiple Sclerosis (MS), Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Chronic Progressive
- Trial name
- ReVIVE (NCT05359653)
- Testing
- Clemastine Fumarate
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- University of California, San Francisco